# data[].attributes.attachment_link.readable_text
O câncer de mama é o segundo mais prevalente entre as mulheres, após as neoplasias de pele não melanoma. No contexto brasileiro, esse tipo de câncer corresponde a quase 30% dos novos casos diagnosticados anualmente em mulheres, sendo também a principal causa de morte nesse grupo. Dados atualizados do Instituto Nacional do Câncer (INCA) revelam que as estimativas para o triênio 2023-2025 apontam para um aumento de 10% nos novos casos em relação ao triênio anterior (2020-2022), totalizando cerca de 73.610 casos por ano.

É preocupante observar que essa tendência de aumento de casos no Brasil reflete a média mundial. Para combater essa situação alarmante, torna-se imperativo implementar ações voltadas para a promoção da saúde da mulher, com enfoque especial na detecção precoce do câncer de mama. Estratégias de saúde preventiva e educação sobre o diagnóstico precoce desempenham um papel fundamental na redução das taxas de diagnóstico em estágios avançados, que ainda ultrapassam 50% no país.

Alguns pontos relevantes podem ser observados a partir do dashboard abaixo:

Aumento de Casos: A curva ascendente de casos de câncer de mama no Brasil segue a tendência global, estimando-se cerca de 73.610 novos casos anuais entre 2023 e 2025, de acordo com dados do INCA.

Expansão do Atendimento: O número de pacientes ambulatoriais cresceu consideravelmente, evoluindo 54% entre 2012 e 2022. Isso reflete tanto a maior demanda por tratamento e acompanhamento médico quanto demonstra que o SUS tem se expandido e tendo seu acesso facilitado a cada vez mais pessoas.

Evolução Gradual: O aumento no número de pacientes tem sido constante e gradual ao longo dos anos. Comparando com 2021, houve um incremento de 3% nos pacientes em tratamento.

Foco nas Faixas Etárias: Em 2022, aproximadamente 76% das pacientes (222.701) tinham idades entre 40 e 69 anos, reforçando a importância de monitorar de perto essa faixa etária.

Centros de Tratamento: Atualmente, o Brasil dispõe de 249 centros de tratamento para o câncer de mama em 23 unidades federativas, demonstrando um tímido crescimento em relação aos períodos anteriores.

Quanto antes o câncer de mama for diagnosticado, melhores serão os resultados no tratamento
Para alcançar melhores resultados no tratamento do câncer de mama, é fundamental diagnosticá-lo precocemente. Quanto mais cedo o diagnóstico ocorrer, maiores serão as chances de sucesso no tratamento. Estudos mostram que nos estágios iniciais, a sobrevida em 5 anos varia entre 93% e 100%, enquanto em estágios mais avançados, essas taxas não passam de 70% a 72%. Portanto, o incentivo ao rastreamento e ao diagnóstico precoce é crucial para melhorar os resultados dos tratamentos.

O Brasil ainda enfrenta desafios significativos, com a maioria das pacientes em estágios mais avançados. Em 2022, a maioria das pacientes em tratamentos no SUS se encontravam no estadio III (75.145), enquanto o menor índice de pacientes estava no primeiro estadio (43.277).

Em relação às faixas etárias, a maior concentração de pacientes se encontra entre 40 e 69 anos, com 222.701 pacientes, representando aproximadamente 75% do total de pacientes em tratamento.

Para melhorar esse cenário, é necessário desenvolver políticas públicas embasadas em evidências, que incluam programas de detecção e rastreamento do câncer de mama na população, além de ampliar e descentralizar unidades de referência para o tratamento da doença em regiões com escassez de assistência. A batalha contra o câncer de mama no Brasil requer ações coordenadas que incluam medidas preventivas, educação, acesso facilitado a tratamentos e investimentos em centros especializados. A detecção precoce permanece como a chave para garantir resultados mais promissores no tratamento e melhorar a qualidade de vida das pacientes.

# data[].attributes.attachment_link.title
Observatório de Oncologia » Indicadores de Câncer de Mama

# data[].attributes.attachment_link.description
O câncer de mama é o segundo mais prevalente entre as mulheres, após as neoplasias de pele não melanoma. No contexto brasileiro, esse tipo de câncer corresponde a quase 30% dos novos casos diagnosticados anualmente em mulheres, sendo também a principal causa de morte nesse grupo. Dados atualizados d…

# data[].attributes.headline
observatorio cancer de colo uterino Brasil 

# data[].attributes.subject
observatorio cancer de colo uterino Brasil 

# data[].attributes.attachment_link.readable_text
O câncer do colo do útero é um dos mais frequentes tumores na população feminina e a principal causa da doença é a infecção persistente pelo Papilomavírus Humano (HPV). A infecção genital por esse vírus é muito frequente e não causa doença na maioria das vezes. Entretanto, em alguns casos, ocorrem alterações celulares que podem evoluir para o câncer. Essas alterações são descobertas facilmente no exame preventivo (conhecido também como Papanicolau) e são curáveis na quase totalidade dos casos (Instituto Nacional de Câncer - INCA, 2019).

Os dados deste dashboard nos mostram alguns pontos importantes:

A estimativa do INCA é de 17.010 novos casos para cada ano do triênio 2023-2025, sendo o terceiro mais comum entre mulheres, depois apenas de Câncer de Mama e Câncer de Cólon e reto.

Nos últimos doze anos (2012-2023) houve ligeira redução (-3%) na incidência do câncer de colo do útero, de acordo com o INCA. Porém, houve aumento significativo (46%) na quantidade de pacientes que realizaram procedimentos no ambiente ambulatorial com financiamento SUS. Em 2022 foram aproximadamente 50 mil pacientes no ambiente ambulatorial e 19 mil no ambiente hospitalar. Uma hipótese para essa desproporção entre incidência e pacientes no SUS seria as estimativas do INCA estarem subestimadas.

Pacientes entre 30 e 69 anos representam 83% dentre os que realizaram procedimentos ambulatoriais em 2022, sendo a faixa etária de 40-49 anos a mais incidente (26%) e também a que apresentou maior aumento de 2012 para 2022 (59%).

Em 2022, 63% das pacientes que realizaram procedimentos no ambiente ambulatorial fizeram procedimentos com finalidade diagnóstica (31.344 pacientes), seguido por 51% de procedimentos clínicos (25.055 pacientes).

Dentre os procedimentos clínicos de 2022, 48% das pacientes realizaram radioterapia, sendo que esta manteve-se praticamente estável nos últimos 11 anos, enquanto as quimioterapias cresceram significativamente. Ainda neste ano, a quimioterapia avançada representou 39% das pacientes em quimioterapia, aumento de 54% nos últimos 10 anos. Enquanto a quimioterapia em estadios iniciais representou 61% e aumento de 34%. Importante ressaltar que este crescimento na quimioterapia avançada ocorreu mesmo com valor de reembolso por procedimento menor que em estadios iniciais: R$571,50 vs R$1.300. Esses valores não sofreram nenhum reajuste de 2012 a 2022.

Muito importante mencionar que além do aumento das pacientes em tratamento, que pode ser reflexo de aumento de acesso ao tratamento e diagnóstico, os óbitos também cresceram significativamente ao longo destes 9 anos (32%), com 7.434 mortes em 2020. O Câncer de Colo de Útero é o quarto que mais mata mulheres com Câncer, de acordo com o Indicadores de Oncologia.

A quantidade de centros de tratamento teve um aumento 24% no período de 2012 para 2022, passando de 192 para 238 centros no país. As regiões com mais centros de tratamento em 2022 foram Sudeste (48%), Sul (24%) e Nordeste (18%) e as que mais aumentaram a quantidade de centros foram Sudeste com 20 novos centros e Nordeste com 13.
Controle e redução do câncer de colo uterino
Sabe-se que as taxas de incidência e diagnóstico podem variar conforme a implementação e o acesso a programas de prevenção e controle efetivos do câncer de colo uterino. Além disso, as taxas podem ser impactadas por mudanças no comportamento da população. De acordo com dados do INCA (2019), fatores que aumentam o risco de desenvolver esse tipo de câncer são:

Início precoce da atividade sexual e múltiplos parceiros.

Tabagismo (a doença está diretamente relacionada à quantidade de cigarros consumidos).

Uso prolongado de pílulas anticoncepcionais.

O controle do câncer de colo de útero compõe o Plano de Ações Estratégicas no Enfrentamento das Doenças Crônicas Não-Transmissíveis (DCNT), do Ministério da Saúde. Em 2016, foram lançadas as Diretrizes de Rastreamento do Câncer de Colo de Útero, que incluem a realização de citologia oncótica (Papanicolau) em mulheres assintomáticas na faixa etária de 25 a 64 anos, a cada 3 anos, desde que tenham dois exames realizados anualmente com resultados normais. Em casos de lesão de baixo grau detectada, deve-se realizar um novo exame no intervalo de seis meses. É muito importante ressaltar que o câncer de colo de útero é altamente prevenível e, quando as alterações (lesões precursoras) que antecedem o câncer são identificadas e tratadas, a porcentagem de prevenção da doença é alta.

Desde 2014, a vacina tetravalente contra o HPV (tipos 6, 11, 16 e 18) faz parte do Calendário Oficial de Vacinação do Ministério da Saúde, para meninas na faixa etária de 9 a 13 anos. A partir de 2017, passou a fazer parte para os meninos de 11 a 13 anos. A vacinação das crianças, em idade antes do início da atividade sexual, é uma excelente forma de evitar o contágio pelo HPV (vírus sexualmente transmissível) e com potencial de erradicar o câncer de colo de útero no futuro. Porém, a cobertura vacinal ainda é baixa.

Para melhoria deste cenário no Brasil, são necessárias políticas públicas baseadas em evidências e que incluam no seu desenvolvimento programas de detecção e rastreamento de câncer na população, além da educação em saúde.

# data[].attributes.attachment_link.title
Observatório de Oncologia " Indicadores de Colo do Útero

# data[].attributes.attachment_link.description
O câncer do colo do útero é um dos mais frequentes tumores na população feminina e a principal causa da doença é a infecção persistente pelo Papilomavírus Humano (HPV). A infecção genital por esse vírus é muito frequente e não causa doença na maioria das vezes.

# data[].attributes.headline
lancet global incidence mortality cervical cancer  who iniciative

# data[].attributes.subject
lancet global incidence mortality cervical cancer  who iniciative

# data[].attributes.attachment_link.title
Estimativa 2023: incidência de câncer no Brasil

# data[].attributes.attachment_link.description
A Estimativa 2023 traz dados de incidência de câncer e representa uma ferramenta importante para o desenvolvimento do sistema de vigilância no país.

# data[].attributes.attachment_link.description
Women face a range of challenges when it comes to cancer, from biological and medical effects to psychosocial concerns, financial well-being, exposure to risk factors, and discrimination.

# data[].attributes.headline
Closing the Women’s Health Gap: A $1 TrillionOpportunity to ImproveLives and Economies

# data[].attributes.subject
Closing the Women’s Health Gap: A $1 TrillionOpportunity to ImproveLives and Economies

# data[].attributes.body
Health Gap: A $1 Trillion

Opportunity to Improve

Lives and Economies

# data[].attributes.attachment_link.readable_text
Over the past two centuries, the rise in life expectancy-for both men and women-has been a tremendous success story. Global life expectancy increased from 30 years to 73 years between 1800 and 2018. But this is not the full picture. Women spend more of their lives in poor health and with degrees of disability (the "health span" rather than the "life span"). A woman will spend an average of nine years in poor health, which affects her ability to be present and/or productive at home, in the workforce, and in the community and reduces her earning potential (see sidebar "Terminology used in this report").

Critically, better health is correlated with economic prosperity. The women's health gap equates to 75 million years of life lost due to poor health or early death per year (Exhibit 1), the equivalent of seven days per woman per year. Addressing the gap could generate the equivalent impact of 137 million women accessing full-time positions by 2040. This has the potential to lift women out of poverty and allow more women to provide for themselves and their families. Addressing the drivers of this gap-namely, lower effectiveness of treatments for women, worse care delivery, and lack of data-would require substantial investment but also reflect new market opportunities.

While improving women's health has positive economic outcomes, it is foremost an issue of health equity and inclusivity. Addressing the women's health gap could improve the quality of life for women, as well as creating positive ripples in society, such as improving future generations' health and boosting healthy aging.

The challenges women face when seeking healthcare play out in multiple different ways and in different diseases and sectors of society. In terms of the potential economic impact of addressing these challenges, all age groups and geographies could benefit, with most of the potential coming from women of working age (Exhibit 2).

Embracing the full definition of women's health

Women are most likely to be affected by a sex-specific condition between the ages of 15 and 50. Other conditions occur throughout women's lives, but nearly half of the health burden affects women in their working years, which often has an impact on their ability to earn money and support themselves and their families (Exhibit 4).

Health equity encompasses access to the interventions and options that are right for each individual, regardless of their gender, sex, sexual identity, sexual orientation, age, race, ethnicity, religion, disability, education, income level, or any other distinguishing characteristic. For women, this can start with a better understanding of and access to interventions that lead to the best outcomes.

How to read this report

The analysis presented in this report includes an assessment of the health burden associated with the women's health gap as measured in potential years of healthy life. This health improvement potential was then translated to economic potential, measured as contribution to gross domestic product (GDP). Sections 2 through 4 of this report focus on health improvement potential (measured in DALYs), broken down by three root causes related to disparities in science, data, and care delivery. The economic value of this combined health improvement potential is presented in section 6, where economic impact is measured in terms of additional GDP.

While this report focuses on the potential economic benefits of closing the women's health gap, there is also a moral imperative to close the women's health gap and to improve the lives of millions of women worldwide.

Effectiveness of and access to medical therapies may vary

There are well-known cases where women and men experience important differences in the uptake or effectiveness of a medicine designed and approved for use in both sexes. This is true, for example, for some therapies used in asthma and cardiovascular disease. Analysts looked at 183 of the most widely used interventions across 64 health conditions representing roughly 90 percent of the health burden for women, reviewing more than 650 academic papers, to assess the extent of this phenomenon. Of the interventions studied 50 percent reported sex-disaggregated data. In cases where sex-disaggregated data was available, 64 percent of the interventions studied were found to put women at a disadvantage due to lower efficacy, more limited access, or both, while for men this was the case only for 10 percent of interventions (Exhibit 5).

Examples include:

Asthma is a common respiratory condition affecting men and women at similar prevalence rates. Acute asthma exacerbations present as symptoms such as shortness of breath, wheezing, cough, or chest tightness. A mainstay of treatment is inhaler therapy with bronchodilators and corticosteroids, but studies indicate that this treatment is around 20 percentage points less effective in reducing exacerbations in women than in men.

Cardiovascular and cerebrovascular disease-particularly ischemic heart disease and stroke-is the biggest single contributor to disease burden globally for both men and women, accounting for 16 percent of DALYs globally for men and 14 percent for women. One German study found that, despite identical technical success of a percutaneous cardiac intervention for men and women, the age-adjusted risk of death or of cardiac events was 20 percent higher in women than in men.

Research in women's health primarily focuses on diseases with high mortality, overlooking diseases leading to disability

One way to assess research priorities is through pipeline assets. There is up to a tenfold higher volume of new therapies in development for some of the most common women's cancers compared with debilitating gynecological conditions (Exhibit 6). One possible reason is the higher mortality rate of oncologic conditions. The solution is not to trim cancer funding, but to recognize the possibilities for advances in research related to other women's health conditions-in particular, menopause, premenstrual syndrome, endometriosis, and polycystic ovary syndrome.

In all, when tackling women's health, the solution is not to divide more slices of one pie: it's to make more pie.

How the lack of sex- and gender-specific data and research affects safety

The research conducted indicates that systematic lack of disease understanding created a women's health gap of 40 million to 45 million DALYs per year, or four days per woman per year. This is equivalent to around 60 percent of the total gap due to sex-related biology differences (see Exhibit 1 above). This estimate includes the known gap for conditions that affect both sexes and an estimate of the gap represented by the average lower effectiveness for women-specific conditions relative to men. It also includes the "unknown" gap: this is where no sex-disaggregated evidence is available for specific conditions that could, if evidence existed, potentially demonstrate levels of effectiveness difference comparable to conditions where sex-based analysis is available. The longevity of women cannot explain the disparity, and the effectiveness gap has a disproportionate impact on women and girls between ten and 40 years old and in certain regions (Latin America and Central Asia).

Shining a light on the interventions for which this information was not reported would benefit both men and women by enabling innovators to develop interventions that are better suited for specific subpopulations.

Gaps exist across the data value chain

Stage 1: Pre-data generation

The data gap starts at the very definition of women's health. There is a lack of consistent and aligned definitions and measurement scales for conditions and symptoms affecting women. For example, definitions of health-related burden associated with menopause or menstrual syndromes differ, and pain instruments and scales lack consistency.

Stage 2: Data generation

Stage 3: Data aggregation

Stage 4: Data analysis

Women can face barriers to timely and accurate diagnosis

Gaps in understanding the effectiveness of health interventions

Ensuring sex-differentiated results

Representative clinical studies capable of producing stratified results may involve larger and longer clinical trials, increasing costs and extending time to market. However, the results would likely lead to more effective interventions with higher uptake among patients. The risk/reward equation for investors becomes more balanced if payers (governments, insurers, and patients) and regulators insist on evidence for cohort-specific impact.

Today, some conditions, such as leukemia and meningitis, are believed to affect men and women equally. But the research to identify potential differences is lacking. Stakeholders may explore how a systematic and proactive approach to designing and reporting clinical outcomes could take sex and gender into account.

Inequalities exist throughout the full pathway of care

The care pathway runs from awareness of a health issue to access to services and preventive care, timely and accurate diagnosis and effective treatment and follow-up. At each segment of this pathway, inequalities exist, especially for women who are disadvantaged in ways beyond their gender (see sidebar "Intersectionality and health outcomes").

Awareness and prevention

The importance of increasing awareness goes beyond patients. Many doctors are unaware of how diseases can affect or manifest differently in women, so they are unable to provide proper care to many patients.

Accessibility and affordability of care

Timely diagnosis

Choice of treatment

Creating solutions to tackle care disparities

Overall, the gap in care delivery contributes 34 percent to the women's health gap (see Exhibit 1 above). Consider how sex- and gender-appropriate care delivery could reduce the women's health burden by 25 million DALYs per year globally, corresponding to 2.5 days per woman per year.

Improvements in the diagnostic tools available would represent a major step forward for patients. Yet even without innovative tools, it would be possible to improve care and bridge the gaps in diagnosis with more consistent and standardized screening and data collection. Earlier diagnosis and a more holistic, patient-centric treatment approach could help improve disease and symptom management, prevent uncontrolled progression and resulting complications, and reduce unnecessary treatments.

At a global level, AI, unbiased data sets, and interoperable electronic records are potential options for enhancing care delivery. Ultimately, a combination of innovation, investment, and ability to scale could unlock better care delivery solutions for women.

There has been a historical underinvestment in women's health research from the public, social, and private sectors. Funding sources typically overlook the fact that many conditions manifest differently in each sex, creating variances in outcome.

Closing the health gap will require increased investment not only for understanding sex-based differences but also for addressing unmet needs in women's health. Further, additional funding and new business models could support sex- and gender-appropriate care.

Research funding neglects women's health

Private equity/venture capital investors are increasing investments in women's health, with excitement about digital health solutions

Given the large unmet need and resulting opportunity, those who continue to forgo investing in women's health may find themselves left behind by the players that tap into this high-potential market.

The disparities in women's health affect not only women's quality of life but also their economic participation and ability to earn a living for themselves and their families. Health is intricately linked to economic productivity, prospects for prosperity, and contribution to economic output. Economic growth over the past 70 years has been closely tied to women's increased labor force participation. Therefore, it is not surprising that the gap in women's health results in lost economic potential.

Addressing the health gap women face could boost the global economy by adding at least $1 trillion to the global economy by 2040. This means a 1.7 percent increase in the average per capita GDP generated by women.

Women's economic participation has been and will be a major driver of economic growth

Addressing the gap could generate the equivalent impact of 137 million women accessing full-time positions by 2040. This would enable women to secure an income to support themselves and their families and has the potential to lift more women out of poverty.

Better health often enables individuals to work more effectively

Looking at the different channels affecting GDP, the largest impact, amounting to around $400 billion or avoiding 24 million years with disability, would be created through fewer health conditions (Exhibit 9). Expanded participation and increased productivity could each contribute more than 20 percent of total impact.

Treating ten health conditions would contribute more than half of the economic impact

The conditions having the greatest economic impact in different countries will differ from one geographic region to another based on each region's disease burden and healthcare status. The examination of economic impact, rather than DALY impact, gives more weight to conditions that affect people during years of working age, as that is when economic contribution is highest. Conditions such as ischemic heart disease may affect more people, but if the burden of morbidity and premature mortality happens after the usual age of retirement, the economic impact is more limited.

Generally, a reduction in health conditions is tied to a woman's economic potential, with allowances for regional socioeconomic and healthcare factors (Exhibit 11). The top two conditions by contribution to GDP impact of the women's health gap are always a combination of two of the top four global conditions: PMS, depression, migraine, or other gynecological conditions. Larger differences among regions are observed when looking at the top ten or more conditions.

Across the four channels, the highest GDP impact relative to women's GDP is observed in HICs and LICs (Exhibit 12). For LICs, most of the impact comes from fewer early deaths and fewer health conditions. Both upper-middle-income (UMIC) and lower-middle-income (LMIC) regions exhibit an overall lower projected GDP impact.

Investing in women's health shows positive return on investment (ROI): for every $1 invested, approximately $3 is projected in economic growth

The expected economic return varies by region. The ROI is greatest in higher-income settings, where it is around $3.50 returned for every $1 invested. More investment is probably needed in some LICs to establish the basic health infrastructure required to support low-cost delivery of high-quality health services, as well as to create better and more rewarding economic opportunities for women. Still, the analysis indicates that the overall benefit would exceed the costs even in these settings, at a rate of around $2 returned on $1 invested.

The analysis examines only the direct costs of addressing the gaps in care delivery identified. In the longer term, a range of greater positive returns is possible, given that improvement in the lives of women influences the health and resilience of their families and communities.

Where to start tackling the women's health gap to reap the greatest benefit for all

Globally, the top ten conditions by economic impact account for more than 50 percent of the total GDP impact. This highlights areas with high unmet needs and potential, aiding decision makers in prioritizing efforts to address health disparities. Specific conditions and their socioeconomic contexts vary among regions, influencing their contribution to the economy. This information could guide tailored strategies toward health equity.

The content and sequence of each action will need to be tailored to regional conditions. Building on the knowledge developed throughout this report, a fact-based strategic assessment can lead to better health equity for each country.

As noted in this report, women's health has been under-researched, and women face different challenges from men in affordability and access to treatment. This health gap creates unnecessary suffering and preventable economic losses.

It does not have to be this way. Through collaborative efforts on five fronts, a more equitable and healthy future is possible. There is an opportunity to close the women's health gap by (1) investing in women-centric R&D, (2) strengthening the collection and analysis of sex- and gender-disaggregated data, (3) enhancing access to gender-specific care, (4) encouraging investments in women's health innovation, and (5) examining business policies to support women.

Invest in women-centric research to fill the knowledge and data gaps in women-specific conditions, as well as in diseases affecting women differently and/or disproportionately

The women's health gap could be narrowed by increasing funding to achieve equality with investments in funding for men's health and using protocols that set standards of equity and diversity. Scientists, life science companies (pharma, biotech, medtech), healthcare providers, and others in the healthcare ecosystem may consider how the traditional understanding of disease is focused primarily on the male body. A more in-depth understanding of these differences would enable more effective care interventions and improved health outcomes. One example of venture-capital-backed funding addressing this disparity is Repro Grants, which allots up to $100,000 for research projects aimed at deepening understanding of female reproductive biology.

For conditions that affect women differently or disproportionately, more effective interventions start with clinical trials designed with inclusivity at their core, informed by preclinical research using female animal models. Specifically, there should be stronger diversity, equity, and inclusion guidelines for clinical trial design. Guidance could incorporate male versus female disease prevalence mix and use sex-specific thresholds for biomarkers to yield an adequate patient representation in clinical trials.

Systematically collect and analyze sex-, ethnicity-, and gender-specific data to have more accurate representation of women's health burden and the impact of different interventions

The prevalence of conditions such as endometriosis and menopause is underestimated, leading investors and life science companies to underestimate the market potential of these conditions and underinvest. By accurately assessing and reporting on the prevalence of such conditions, national health institutes and other authorities may direct additional funding to the research and treatment of these underserved conditions.

Biotech, medtech, and FemTech enterprises also have exciting opportunities related to AI and ML, which ensures that these models do not exacerbate existing biases or violate patient privacy rules. Developing robust, secure, and holistic data sets could enable companies to differentiate in an overcrowded marketplace.

Enhance access to gender-specific care, from prevention to diagnosis and treatment

Women deserve the same high-quality level of care from their healthcare providers as men, which doesn't mean the same care per se. There is a pressing need to redesign medical curricula as well as residency and fellowships to reflect sex and gender differences. In addition to medical schools, continuing medical education organizations and credentialing entities could assess whether healthcare providers are receiving the latest information and training on the women's health gap and sex- and gender-based differences. Current and future healthcare professionals of all specialties must be equipped with accurate and updated knowledge of biological differences, including sex-specific manifestations of symptoms. Future certification or tests could include questions meant to address whether providers have internalized this knowledge.

Governments, educational bodies, philanthropic institutions, and many other stakeholders can use this moment to raise awareness of the sex-specific manifestations of disease-for example, ensuring that newly diagnosed endometriosis patients have access to up-to-date resources, including which trials they could potentially participate in. Healthcare entities, philanthropic organizations, or community health workers could start or reinvigorate in-person support groups for conditions such as endometriosis or menopause or for mental health support. Collectively, better education and resources, plus new diagnostics, are among the ways to potentially elevate the quality of healthcare women receive.

In addition, two things to enable closing the gap include:

Create incentives for new financing models to close the women's health gap

Historically, given lower levers of investments overall for women's health under the traditional financing model schemes, new financing models have a critical role to play. These models can accelerate innovation. One example is the advance market commitment (AMC) geared to COVID-19 vaccine development and deployment.

Research and reliable data on the women's health landscape can help spur investment. For investors, the gender-based healthcare landscape presents a mosaic of unexplored opportunities. By pivoting toward this opportunity, investors can channel funds into high-impact areas, bridge the data gap, and enable more investment and innovation.

Governments could explore policies that encourage sex- and gender-responsive health research and services-for example, by earmarking funds, providing tax incentives, lowering application fees, and expediting the drug approval process. Philanthropic organizations, donors, and international bodies could offer grants and prizes at a national or local level to spur innovation while supporting capacity building in regions where gender-based health disparities are highest. Examples might be launching a grant or award program geared toward reducing rates of respiratory illnesses in areas where there is a high percentage of women smokers, or toward a technology-based solution for women in vulnerable populations to access transportation to healthcare services.

With collaboration, stakeholders have the potential to encourage investments and inspire the development of innovative financing models in women's health.

Establish business policies that support women's health

Data-driven, scalable actions to improve women's health may vary widely, but the critical component is to determine how each stakeholder can contribute to narrowing the gap.

If health equity efforts sit within a tree of principles, they can be watered by research, flourish in the sun of business investments, and grow far-reaching branches that stretch into the economy.

Achieving health equity is a collaborative and ongoing endeavor that relies on the active participation of governments, healthcare institutions, nongovernmental organizations, individuals, and all stakeholders vested in this cause. Tackling the women's health gap depends on addressing the interconnected factors outlined in this report: the deficit of women-specific knowledge in science, the glaring data gaps, the disparities in healthcare delivery, and the insufficient investment in women's health.

Recognizing the vast potential to improve the lives and livelihoods of half the global population while boosting the economy serves as the catalyst for closing the women's health gap. Every facet of this gap, from limited education to suboptimal treatments, offers an opportunity for transformation with the active involvement of governments, life science innovators, educational institutions, philanthropists, activists, and more.

In this endeavor lies an opportunity of $1 trillion in economic potential driven by improved women's health and economic participation. The question is not whether this wealth of opportunities exists but rather who will take the initiative to seize it and drive change.

Women's health is not a stand-alone issue; it is a cornerstone of societal well-being and progress. Better health and well-being for women creates a ripple effect that extends to families, communities, and nations. This holistic approach, supported by collective action and sustained investment, will not only narrow the health gap but also contribute to the betterment of a shared global future.

# data[].attributes.attachment_link.title
Closing the women's health gap: A $1 trillion opportunity to improve lives and economies

# data[].attributes.attachment_link.description
Investments addressing the women's health gap could add years to life and life to years-and potentially boost the global economy by $1 trillion annually by 2040.

# data[].attributes.headline
objetivos modelo cdc para programas de dtecção precoce mama e coclo uterino 

# data[].attributes.subject
objetivos modelo cdc para programas de dtecção precoce mama e coclo uterino 

# data[].attributes.headline
apresentacao resumida utero é vida jul 2023

# data[].attributes.subject
apresentacao resumida utero é vida jul 2023

# data[].attributes.attachment_link.title
APRESENTAÇÃO RESUMO PROJETO PERNAMBUCO  jul 2023 tjcc

# data[].attributes.headline
blue book CCU HPV  rastreamento OPAS 2019

# data[].attributes.subject
blue book CCU HPV  rastreamento OPAS 2019

# data[].attributes.headline
programa do CDC  USA populações vulneraveis 

# data[].attributes.subject
programa do CDC  USA populações vulneraveis 

# data[].attributes.attachment_link.readable_text
CDC's National Breast and Cervical Cancer Early Detection Program (NBCCEDP) provides breast and cervical cancer screenings and diagnostic services to women who have low incomes and are uninsured or underinsured.

Select a state, territory, or tribe below to see the award recipient's contact information and screening program summaries. Note that screening program data are not shown for award recipients with fewer than 200 served or cell sizes less than 16.

Are You Eligible for Free or Low-Cost Screenings?

You may be eligible for free or low-cost screenings if you meet these qualifications-

You have no insurance, or your insurance does not cover screening exams.

Your yearly income is at or below 250% of the federal poverty level.

You are between 40 and 64 years of age for breast cancer screening.

You are between 21 and 64 years of age for cervical cancer screening.

Certain women who are younger or older may qualify for screening services.

To find out if you qualify for free or low-cost breast and cervical cancer screening services in Program and where to get screened, contact-

ProgramSSI

Five-Year Summary: July 2017 to June 2022

Data are suppressed for award recipients with fewer than 200 served.

# data[].attributes.attachment_link.description
CDC's National Breast and Cervical Cancer Early Detection Program (NBCCEDP) provides breast and cervical cancer screenings and diagnostic services to low-income, uninsured, and underinsured women across the United States.

# data[].attributes.attachment_link.title
Global strategy to accelerate the elimination of cervical cancer as a public health problem

# data[].attributes.attachment_link.description
When autocomplete results are available use up and down arrows to review and enter to select.

# data[].attributes.attachment_link.title
WHO guideline for screening and treatment 20202

# data[].attributes.attachment_link.readable_text
A test to detect human papillomavirus (HPV) in cervical samples was developed based on the evidence that persistent infection with certain HPV types was necessary for the development of nearly 95% of cervical cancers. There is now compelling evidence that HPV tests are superior to cervical cytology (Pap smear) or visual inspection of the cervix with acetic acid (VIA) in detecting cervical precancer and cancer; thus, they are the most suitable cervical screening test.

In November 2020, the World Health Organization (WHO) launched a global initiative to accelerate the elimination of cervical cancer as a public health problem worldwide. Elimination of this virus-induced cancer is feasible through vaccination against HPV, screening with HPV testing, and appropriate treatment of the screen-detected precancers and cancers. Prevention of cervical cancer will have a far-reaching global impact, given that more than 300 000 women per year still die from this cancer and that more than 80% of these deaths occur in low- and middle-income countries.

Modelling studies have shown that achievement of the following targets by all countries by 2030 will reduce cervical cancer incidence to fewer than 4 new cases per 100 000 women per year globally (from 13.3 new cases per 100 000 women in 2020) by 2100:

90% of girls are fully vaccinated with the HPV vaccine by the age of 15 years;

70% of women are screened using a high-performance test (e.g. HPV test) by the age of 35 years, and again by the age of 45 years;

90% of women diagnosed with cervical precancer or cancer receive appropriate treatment.

# data[].attributes.attachment_link.title
Using HPV tests for cervical cancer screening and managing HPV-positive women - a practical online guide

# data[].attributes.attachment_link.description
A test to detect human papillomavirus (HPV) in cervical samples was developed based on the evidence that persistent infection with certain HPV types was necessary for the development of nearly 95% of cervical cancers.

# data[].attributes.attachment_link.readable_text
Almost all cervical cancers are caused by HPV. The body can get rid of most HPV infections naturally but if it doesn't, some types of HPV can cause changes to the cells of your cervix. If these cell changes are not picked up early and treated they can turn into cervical cancer.

Cervical cancer is the most common type of cancer caused by HPV. HPV can also cause less common cancers in men and women, like anal, vulvar, vaginal, mouth/throat and penile cancers.

# data[].attributes.attachment_link.description
Almost all cervical cancers are caused by HPV. The body can get rid of most HPV infections naturally but if it doesn't, some types of HPV can cause changes to the cells of your cervix. If these cell changes are not picked up early and treated they can turn into cervical cancer.

# data[].attributes.attachment_link.title
Barriers to uptake of cervical cancer 2022

# data[].attributes.attachment_link.readable_text
Overview

The Global Breast Cancer Initiative, established by WHO in 2021, will provide guidance to governments on health systems strengthening for breast cancer. This illustrated summary outlines its goals, rationale and framework.

# data[].attributes.attachment_link.title
The Global Breast Cancer Initiative (GBCI)

# data[].attributes.attachment_link.description
﻿The Global Breast Cancer Initiative, established by WHO in 2021, will provide guidance to governments on health systems strengthening for breast cancer. This illustrated summary outlines its goals, rationale and framework.

# data[].attributes.attachment_link.title
banco slides ação educacional mama e ccu  mulher out 2023

# data[].attributes.attachment_link.title
diligencia 2021-  educação permanenente em oncologia do IMIP pronon  2017   quinta 03 nov 

# data[].attributes.attachment_link.title
resumo 3 projetos pronon para execução 2022 

# data[].attributes.attachment_link.title
pronon tele educação 2020 1  23 de junho de 2021 CORRIGIDO  jul 22

# data[].attributes.attachment_link.description
The Future of Jobs Report 2023 explores how jobs and skills will evolve over the next five years. This fourth edition of the series continues the analysis of employer expectations to provide new insights on how socio-economic and technology trends will shape the workplace of the future.

# data[].attributes.attachment_link.readable_text
The NHS Long Term Plan (LTP) was published in January 2019. It sets out stretching ambitions and commitments to improve cancer outcomes and services in England over the next ten years.

The key ambitions in the NHS LTP for cancer are:

by 2028, 55,000 more people each year will survive their cancer for five years or more; and

by 2028, 75% of people with cancer will be diagnosed at an early stage (stage one or two).

The ambitions will be delivered in a way that:

improves quality of life outcomes;

improves patient experience outcomes;

reduces variation; and

reduces inequalities

The NHS Cancer Programme is responsible for delivering on the LTP for cancer. The LTP ambitions build on and accelerate the significant progress already made through delivery of the recommendations of the Independent Cancer Taskforce published in 2015. You can read more about the we've made to deliver the Taskforce's recommendations in our progress reports.

You can also read the NHS Cancer Programme's latest update report which sets out the key achievements from October 2019 to January 2020 in delivering the NHS Long Term Plan for cancer.

# data[].attributes.attachment_link.description
The NHS Long Term Plan (LTP) was published in January 2019. It sets out stretching ambitions and commitments to improve cancer outcomes and services in England over the next ten years.

# data[].attributes.attachment_link.readable_text
An ambitious 10-year action plan to achieve equitable access to quality cancer care in Canada and ensure a sustainable system for the future

View your jurisdiction's progress towards the cancer strategy priorities

View progress

How is the Strategy helping me and those I care about?

# data[].attributes.attachment_link.title
Cancer Strategy - Canadian Partnership Against Cancer

# data[].attributes.attachment_link.description
Le Partenariat canadien contre le cancer a publié la version actualisée de la Stratégie canadienne de lutte contre le cancer - une feuille de route sur 10 ans visant à améliorer l'équité au sein du système de lutte contre le cancer et à soutenir ceux qui ont le plus besoin d'aide, tout en se concentrant sur la mise en place d'un système de santé durable pour l'avenir.

# data[].attributes.attachment_link.title
SCON2020-00146 - INSTITUTO DE MEDICINA INTEGRAL PROFESSOR FERNANDO FIGUEIRA - IMIP (3)

# data[].attributes.attachment_link.title
The Cochrane HPV vaccine review was incomplete

# data[].attributes.attachment_link.readable_text
A test to detect human papillomavirus (HPV) in cervical samples was developed based on the evidence that persistent infection with certain HPV types was necessary for the development of nearly 95% of cervical cancers. There is now compelling evidence that HPV tests are superior to cervical cytology (Pap smear) or visual inspection of the cervix with acetic acid (VIA) in detecting cervical precancer and cancer; thus, they are the most suitable cervical screening test.

In November 2020, the World Health Organization (WHO) launched a global initiative to accelerate the elimination of cervical cancer as a public health problem worldwide. Elimination of this virus-induced cancer is feasible through vaccination against HPV, screening with HPV testing, and appropriate treatment of the screen-detected precancers and cancers. Prevention of cervical cancer will have a far-reaching global impact, given that more than 300 000 women per year still die from this cancer and that more than 80% of these deaths occur in low- and middle-income countries.

Modelling studies have shown that achievement of the following targets by all countries by 2030 will reduce cervical cancer incidence to fewer than 4 new cases per 100 000 women per year globally (from 13.3 new cases per 100 000 women in 2020) by 2100:

90% of girls are fully vaccinated with the HPV vaccine by the age of 15 years;

70% of women are screened using a high-performance test (e.g. HPV test) by the age of 35 years, and again by the age of 45 years;

90% of women diagnosed with cervical precancer or cancer receive appropriate treatment.

# data[].attributes.attachment_link.title
Using HPV tests for cervical cancer screening and managing HPV-positive women - a practical online guide

# data[].attributes.attachment_link.description
A test to detect human papillomavirus (HPV) in cervical samples was developed based on the evidence that persistent infection with certain HPV types was necessary for the development of nearly 95% of cervical cancers.